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SUMMARY 
Limited data exists describing the long-term prognosis of patients with acute 
decompensated heart failure (ADHF) further stratified according to currently 
recommended ejection fraction (EF) findings.  In addition, little is known about the 
magnitude of, and factors associated with, long-term prognosis for these patients. 
Based on previously validated and clinically relevant criteria, we defined HF-REF as 
patients with an EF value ≤40%, HF-PEF was defined as an EF value > 50%, and HF-
BREF was defined as patients with an EF value during their  index hospitalization 
between 41 and 49%.  The hospital medical records of residents of the Worcester (MA) 
metropolitan area who were discharged after ADHF from all 11 medical centers in 
central Massachusetts during the 5 study years of 1995, 2000, 2002, 2004, and 2006 
were reviewed.  Follow-up was completed through 2011 for all patient cohorts.   
The average age of this population was 75 years, the majority was white, and 
44% were men.  Patients with HF-PEF experienced higher post discharge survival rates 
than patients with either HF-REF or HF-BREF at 1, 2, and 5-years after discharge.  
Advanced age and lower estimated glomerular filtration rate findings at the time of 
hospital admission were important predictors of 1-year death rates, irrespective of EF 
findings.   Previously diagnosed chronic obstructive pulmonary disease, chronic kidney 
disease, and atrial fibrillation were associated with a poor prognosis in patients with 
PEF and REF whereas a history of diabetes was an important prognostic factor for 
patients with REF and BREF.   
In conclusion, although improvements in 1-year post-discharge survival were 
observed for patients in each of the 3 EF groups examined to varying degrees, the post-
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discharge prognosis of all patients with ADHF remains guarded.  In addition, we 
observed differences in several prognostic factors between patients with ADHF with 
varying EF findings, which have implications for more refined treatment and surveillance 
plans for these patients. 
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PREFACE 
 
Data from the WHFS (Worcester Heart Failure Study), an observational study of all 
residents of the Worcester metropolitan area hospitalized at all 11 medical centers in 
central MA with acute heart failure between 1995 and 2006, were used to perform the 
analyses outlined herein. 
 
Dr. Coles wrote and designed the analyses outlined in this thesis.  Darleen Lessard MS 
and Dr. Mayra Tizminitesky provided assistance with respect to of the analyses 
performed.  Jerry Gurwitz MD, Chad Darling MD, Kim Fisher MD, Joel Gore, MD, Mayra 
Tizminitesky MD/PhD, and Robert Goldberg PhD provided editorial assistance. 
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CHAPTER 1                  
INTRODUCTION 
 
1.1 Forward 
Cardiovascular disease (CVD) is a leading cause of death worldwide and is associated 
with a substantial economic and healthcare burden [1,2].  Within the broad CVD 
umbrella are five major conditions including stroke, coronary heart disease, arrhythmias, 
heart valve problems, and congestive heart failure.  This thesis will focus on heart 
failure (HF), and in particular, acute decompensated heart failure.  Approximately 5.8 
million American men and women have HF and  there are 23 million cases worldwide 
[3].  The HF epidemic is associated with substantial economic costs and high mortality, 
costing nearly $30 billion per year in healthcare services, medications, and lost 
productivity in 2013 [2,4].  A recent epidemiological study has reported that less  than 1 
in 3 patients with HF discharged from the hospital survive to 5-years [5].  In addition to 
the high mortality associated with HF, it is the leading cause of hospitalizations in the 
elderly accounting for approximately one million hospitalizations annually [4,6,7].  
Controversy currently exists as to the long-term prognosis of patients with HF divided 
into various ejection fraction (EF) strata.  This thesis describes the long-term prognosis, 
and the risk factors that are associated with death at 1-year, of patients with HF divided 
into three EF strata representing reduced (HF-REF; EF≤40%), borderline (HF-BREF; 
EF=41-49%), and preserved (HF-PEF; EF>50%) EF measurements. 
 
1.2 Diagnosis, classification, and lifetime risk of heart failure 
11 
 
Acute decompensated heart failure (ADHF) is an increasingly prevalent complex 
clinical syndrome resulting from impairment in either ventricular filling or ejection of 
blood from the heart [8,9,10].  There is no single diagnostic test for this condition and 
the clinical diagnosis of ADHF is based on medical history and physical examination 
findings [11].  The main symptoms of ADHF are fatigue and dyspnea, which limit 
exercise tolerance, and fluid retention, which can  result in pulmonary congestion or 
peripheral edema [11].  However, the signs and symptoms of ADHF are not specific and 
may be absent at presentation [11].  The Framingham HF criteria is used for  the 
diagnosis of HF and patients must have 2 major criteria or 1 major and 2 minor criteria 
present to be considered as having HF (Table 1.1) [12].  The  diagnosis of HF also 
involves the collection of information by a chest x-ray, echocardiogram, and blood tests 
for specific biomarkers [11].  This data is used to stage HF using either the New York 
Heart Association classification or American College of Cardiology schemas (Table 1.2) 
[9,10,13]. 
An echocardiogram is utilized to determine the ejection fraction (EF), or pumping 
capacity of the heart, which is used to differentiate patients with ADHF into varying 
strata. These groups have typically included patients with , reduced HF, HF-REF [14], 
and those with preserved HF, HF-PEF [15,16].  Studies that have examined EF and its 
association with short and long-term prognosis in patients with ADHF  have, however,  
been inconsistent with the EF cutpoints used, making comparisons between studies 
difficult [3,5,17,18,19,20,21].  The 2013 AHA/ACC guidelines have attempted to clarify 
this concern by proposing three groups based on EF findings [4].  These groups are 
defined as reduced (EF<40%, HF-REF), borderline (EF=41-49%, HF-BREF), and 
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preserved HF (EF>50%, HF-PEF) [4].  In the current work we will use the 2013 
AHA/ACC definitions for these three EF strata [4].  Blood tests for specific biomarkers, 
such as BNP/NT-proBNP and troponins, are being increasingly used by clinicians to 
assist in the diagnosis and selection  of  treatments for patients with, or suspected to 
have, HF  [4,22,23,24,25,26,27,28]. 
 
Table 1.1: Framingham Heart Failure 
Criteria  
    **2 major or 1 major and 2 minor criteria needed for heart failure to be present. 
         Major Criteria 
       Paroxysmal nocturnal dyspnea or 
orthopnea 
    Neck vein distension 
      Rales 
        Cardiomegaly  
       Acute pulmonary edema 
      S3 gallop 
       Increased venous pressure (>16cm water) 
    Circulation time (>25 seconds) 
     Hepatojugular reflux 
      
         Minor Criteria 
       Ankle edema 
       Night cough 
       Dyspnea on excertion 
      Hepatomegaly 
       Plueral effusion 
       Vital capacity decreased one-third of maximum 
   Tachycardia (>120 beats/minute) 
     
         Major or minor criterion 
      Weight loss (>4.5kg) in 5 days in response to treatment 
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Table 1.2: Comparison between the NYHA and ACC/AHA classifications of heart failure 
severity. 
 
    
NYHA Functional 
Classification 
Description ACC/AHA Stages of 
Heart Failure 
Description 
Class I Normal physical activity, no dyspnea on 
excertion 
Stage A At high risk for HF, no symptoms 
Class II Slight limitation of physical activity Stage B Structural heart disease present, no 
symptoms 
Class III Less than ordinary activity causes 
fatigue 
Stage C Structural disease with prior or current 
symptoms 
Class IV Any physical activity causes discomfort Stage D Refractory symptoms to therapy, requires 
special interventions 
14 
 
 
 The lifetime risk for developing HF for a middle aged American man or woman 
(aged 45 years) through 75 years of age differs by gender and race/ethnic group; 
ranging from 20-46% [29,30,31].  A number of individual, and potentially modifiable, risk 
factors for developing HF have been identified.  Major risk factors for HF include 
hypertension, diabetes mellitus, the metabolic syndrome, and atherosclerotic disease 
[3,4].  The etiology of HF has been categorized in clinical trials and routine practice as 
either ischemic or non-ischemic cardiomyopathy, with the terms dilated cardiomyopathy 
(DCM) and non-ischemic cardiomyopathy being used interchangeably in these settings 
[32].   
 
1.3 Pathophysiology and medical management of heart failure. 
1.3.1 Models of HF development and progression 
Current understanding of HF pathophysiology combines several traditional 
models to explain the complex biological alterations seen in HF and to guide therapeutic 
interventions (Figure 1.1) [8,9,15,16,33].  Two major models used to describe the 
abnormalities seen in HF are the hemodynamic model and the neurohormonal model 
[34,35,36].  The hemodynamic model explains the effects of an altered load on 
ventricular filling and is the rationale for the use of vasodilators and inotropic agents.  In 
the neurohormonal model, the impact on HF development of the renin-angiotensin-
aldosterone axis and sympathetic nervous system are explained as is the rationale for 
the use of selected medications including angiotensin-converting-enzyme (ACE) 
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inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and aldosterone 
inhibitors in patients with HF [37].   
 
Figure 1.1: Pathophysiology of acute decompensated heart failure. 
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Another model for HF development and progression is left ventricular remodeling, which 
describes the mechanical, nuerohormonal, and genetic factors that converge to alter 
ventricular size, shape, and ultimately function [9,38,39].  A variety of treatments can 
induce reverse remodeling in which treatment  promotes a return to a more normal 
ventricular size and shape [9].   
Diastolic heart failure, also termed HF-PEF, occurs when the heart contracts 
normally, but the relaxation is abnormal resulting in limited cardiac output especially 
during exercise [16].  Ventricular pressure becomes elevated leading to pulmonary 
congestion, dyspnea, and edema similar to what is seen in patients with HF-REF [9].  
However, in contrast to what occurs in HF-REF, clinical trial data have shown a lack of 
significant benefit from neurohormonal antagonists suggesting that this may not be a 
significant mechanism for the development of HF-PEF [8,16].  Recent studies into the 
pathophysiological mechanisms underlying HF-PEF suggest that it may be a 
heterogeneous disorder resulting from many pathophysiological processes distinct from 
HF-REF [40,41].  These advances have led to better patient related outcomes, but 
further work is needed to improve our understanding of HF pathophysiology, especially 
that of HF-PEF, in order to better treat these patients [16]. 
 
1.3.2 Medical management of HF with reduced EF 
The primary goals of treatment are to improve survival, alleviate symptoms, avoid 
hospital admissions, slow the progression of disease, and to minimize the magnitude 
and impact of risk factors [4,9]. Current evidence-based guidelines have been 
developed for the treatment of patients with HF-REF only and include medications, 
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surgical interventions, and  use of implantable devices [4].  In addition to medical and 
surgical interventions to treat patients with HF, lifestyle modifications; such as sodium 
restriction, weight monitoring, moderation of alcohol intake, and exercise, and improved 
healthcare organization and delivery, have also been suggested to improve patient 
related outcomes [1,4,8,33,42,43,44].  Several non-pharmacologic, non-surgical, and 
non-device treatments have been proposed and advocated, but the evidence base to 
support these interventions is limited [4,14].   
 
1.3.3 Medical management of HF with preserved EF 
 There are currently little evidence-based guidelines directing therapy for patients 
with HF-PEF and the guidelines that do exist are based primarily on consensus opinion.  
Despite the limited efficacy in RCTs involving HF-PEF patients treated with the standard 
HF-REF medications, many practitioners believe that similar pathophysiologic 
processes are occurring in both patient groups and thus similar drugs could be used for 
treatment.  However, one exception are calcium channel blockers which have been 
reported to improve exercise capacity, peak diastolic filling, exercise time, and 
congestive HF score in two very small clinical studies of patients with HF-PEF 
[40,45,46].   
 
1.4 Long-term prognosis of patients with acute decompensated heart failure  
 A number of studies have utilized data from registries, RCTs, and community-
based cohort studies to examine the in-hospital, short, and long-term prognosis of 
patients with ADHF [44].  An observational study of 4,537 residents of Olmsted County, 
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Minnesota who were discharged  from the Mayo Clinic and the Olmsted Medical Center 
with a first diagnosis of HF between 1979 and 2000 found that the 5-year age-adjusted 
survival was worse among men than women  (RR 1.33; 95% CI, 1.24-1.43) [47].  In 
addition, while long-term survival improved for all groups over this period, it improved 
the most among men and younger patients [47].  Similar studies conducted in Ontario 
[48] between 1997-2007 and Scotland [49] between 1986-2003 of patients with HF were 
consistent with the Olmsted County results, finding that survival after HF is very poor 
but has been improving over time.  In the population-based Worcester Heart Failure 
Study, fewer than 1 in 3 patients discharged with ADHF in 2004 survived more than 5 
years. On the other hand,  5 year survival rates improved between 1995 and 2004, 
increasing from 20% in 1995 to 29% in 2004 [5,50].  The overall conclusions from these 
studies and others [51] suggest that patients with HF have a poor long-term survival, 
which has slightly improved over time. 
 The previously cited studies did not, however, stratify patients based on EF 
findings.  A limited number of studies in the 1990’s and 2000’s that did stratify patients 
by EF findings observed that those with a preserved EF had a better prognosis than 
those with a reduced EF [17,52,53].  A large population based cohort of patients with a 
discharge diagnosis of HF from 103 hospitals as part of the Enhanced Feedback for 
Effective Cardiac Treatment (EFFECT) study in Ontario, Canada between 1999 and 
2001 were studied to determine which EF group had a better prognosis [17].  The 
cohort was stratified into three EF groups, less than 40% for the reduced EF group, 40-
50% for the borderline EF group, and greater than 50% for the preserved EF group; 
only the two extreme groups were studied in detail, however.  This study found that 
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patients with reduced and preserved EF had similar 1-year survival and hospital 
readmission rates.  The 1-year unadjusted mortality rate for the HF-REF group was 
26% versus 22% for the HF-PEF group (p=0.07) and the readmission rate at 1-year was 
16. % for the HF-REF group and 14% for the HF-PEF group (p=0.09)  [17].  After 
multivariable adjustment, the mortality rate hazard ratio was 1.13 (95% CI 0.94-1.36) 
[17], suggesting that the HF-PEF and HF-REF groups had a similar mortality 
experience. 
More recently, two papers examined trends in long-term mortality in patients with 
either preserved or reduced EF HF.  The first study was a meta-analysis that compiled 
data from 31 RCTs and observational studies conducted through 2008 with an EF of 
50% differentiating the HF-PEF from the HF-REF group [52].  In this meta-analysis, the 
HF-PEF group had a 32% lower risk of dying from all causes  over three years than the 
HF-REF group, with mortality increasing when EF findings  fell below 40% [52].  The 
second paper summarized the findings from RCTs that enrolled patients with HF-REF 
and/or HF-PEF [53].  Results from this review were consistent with the meta-analysis 
findings suggesting that patients with HF-PEF have a better prognosis than patients 
with HF-REF [53].  The controversy that remains from these few reports highlights the 
necessity of further population based observational studies with broad generalizability to 
determine which patients ,experience higher death rates and /or other outcomes of 
long-term importance  and require more aggressive surveillance and/or tailored 
treatment approaches. 
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1.5 Factors associated with post-hospital discharge mortality among patients 
with ADHF. 
 A number of factors have been identified in association with post-hospital 
discharge mortality among patients with ADHF.  In this work, we will focus on those 
factors that are associated with mortality at 1-year post-hospital discharge due to the 
high incidence of death at this time point (see previous section).   Factors that have 
been reported in the literature include older age, male gender, hyponatremia, lower 
systolic blood pressure, a higher urea nitrogen level, and several comorbid conditions 
(cerebrovascular disease, COPD, hepatic cirrhosis, dementia, and cancer) 
[54,55,56,57,58,59,60].  In addition to these variables, lower EF findings have also been 
found to predict poor long-term survival in the CHARM study for both the composite 
outcome of re-hospitalization and all-cause death and the single outcome of death at 2-
years after hospital discharge [61].  The CHARM study also identified diabetes as an 
important prognostic factor of death in patients with HF [61], as well as a low BMI, low 
diastolic BP, and a prior heart attack.  Reduced renal function has been associated with 
increased all-cause mortality [58,59]. 
 A number of groups have also stratified patients with HF based on EF findings 
into two main groups, preserved and reduced EF HF, and examined factors associated 
with  mortality in these patients [17,62,63,64,65,66].  These studies did not, however, 
use consistent definitions of HF-PEF or HF-REF, making comparisons between studies 
difficult.  In addition, prior studies did not examine the newly identified HF-BREF group 
[4].  A number of these studies used data from clinical trials making the generalizability 
to patients encountered in clinical practice less likely [63,65].  The factors that were 
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found to be important in predicting long-term all-cause mortality depended to some 
extent on whether the patient had either HF-PEF or HF-REF, but several were in 
common.  Predictors of all-cause mortality for patients with HF-REF were low systolic 
and diastolic BP, older age, hyponatremia, renal dysfunction, and peripheral vascular 
disease [17,62].  For patients with HF-PEF, factors associated with an increased risk of 
dying after being discharged from the hospital after ADHF  were older age, peripheral 
vascular disease, hyponatremia, renal dysfunction, low diastolic BP, diabetes, COPD, 
low glomerular filtration rate, and anemia [17,62,65].  The impact of atrial fibrillation (AF) 
on mortality of the HF-REF and HF-PEF groups was also examined recently and was 
shown to adversely  impact mortality and the rates of re-hospitalization in both groups 
[67].   
 
1.6 Observational studies and the Worcester Heart Failure Study (WHFS)  
Randomized clinical trials (RCTs) are the most rigorous study design to establish 
causation and drug efficacy.  However, RCTs have a number of limitations; they use a 
study population with a number of inclusion and exclusion criteria that could decrease 
the generalizability of the findings, they typically exclude patients with multiple 
comorbidities, and in some cases it is not ethical to conduct them, such as to determine 
if a risk factor is an important cause of a disease [68].  Observational studies provide a 
better understanding of what occurs in usual clinical practice and answers questions 
pertaining to the “typical” patient better than an RCT [68].  However, they cannot prove 
causation by themselves, which is a major limitation inherent in the use of these 
designs.  A good example of a prospective observational study is the Worcester Heart 
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Failure Study (WHFS) [69,70].          
 The WHFS cohort is derived from all residents of the greater Worcester 
metropolitan area who had a discharge diagnosis of HF from any of the 11 medical 
centers in central MA during the four study years of 1995, 2000, 2002, and 2004 
(Chapter 4 includes the fifth study year of 2006).  A more detailed discussion of this 
study is presented in Chapter 2: Methods.  In brief, the medical records of patients with 
primary and/or secondary International Classification of Diseases, 9th Revision (ICD-9) 
discharge diagnoses indicating the presence of HF were reviewed by trained nurse and 
physician reviewers.  The present study population used for all analyses in this thesis 
was restricted to individuals who had undergone a clinically indicated echocardiogram 
during their index ADHF-related hospitalization.   
 
1.7 Objectives of this thesis 
There are three main objectives of this thesis using data from the WHFS. These 
are to: 1) describe the characteristics of the three EF subtypes of ADHF; 2) examine the 
long-term outcomes of ADHF stratified by three EF strata; and 3) determine the 
prognostic factors that are associated with mortality at 1-year for the three EF subtypes.  
The first two objectives will be addressed in chapter 3 and the third objective will be 
addressed in chapter 4. 
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CHAPTER 2 
METHODS 
 
Study population 
 The study population consisted of adult residents of the Worcester (MA) 
metropolitan area (2000 census estimate = 478,000) who survived hospitalization for 
ADHF at all 11 central Massachusetts medical centers during the 4 study years of 1995, 
2000, 2002, and 2004 (2006 was added in chapter 4).  These particular years were 
selected for detailed study due to funding availability and to provide insights into decade 
long trends in the clinical epidemiology of ADHF. The present study population was 
restricted to individuals who had undergone a clinically indicated echocardiogram during 
their index ADHF-related hospitalization.  Details of the Worcester Heart Failure Study 
(WHFS) have been described previously [5,70,71].  
In brief, the hospital medical records of patients with primary and/or secondary 
International Classification of Diseases, 9th Revision (ICD-9), discharge diagnoses 
indicating the presence of HF were reviewed in a retrospective manner by trained nurse 
and physician reviewers.  Patients with a discharge diagnosis of HF (ICD-9 code 428) 
comprised the primary diagnostic rubric reviewed.  In addition, the medical records of 
patients with discharge diagnoses of hypertensive heart and renal disease, acute cor 
pulmonale, cardiomyopathy, pulmonary congestion, acute lung edema, and respiratory 
abnormalities were also reviewed to identify patients who may have had new-onset 
ADHF. Confirmation of the diagnosis of HF, based on use of the Framingham criteria, 
included the presence of 2 major criteria or the presence of 1 major and 2 minor criteria 
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[3].  Patients in whom ADHF developed secondary to admission for another acute 
illness (e.g., acute myocardial infarction), or after an interventional procedure (e.g., 
coronary artery bypass surgery), were excluded.   
 
Data Collection 
Information was collected about patient’s demographic characteristics, medical 
history, clinical characteristics, and laboratory test results through the review of 
information contained in hospital medical records. This included information about 
patient’s age, sex, race, prior comorbidities (e.g., angina, diabetes, hypertension, and 
stroke), and clinical characteristics.  Based on the review of medical record data, EF 
findings during the patient’s index hospitalization for ADHF were recorded in 37% of the 
overall study cohort.  Based on previously validated and clinically relevant criteria, we 
defined HF-REF as patients with an EF value ≤40%, HF-PEF was defined as an EF 
value > 50%, and HF-BREF was defined as patients with an EF value during their  index 
hospitalization between 41 and 49% [3,4,72,73,74].   
Physician’s progress notes were reviewed, in addition to the daily medication 
logs, for the prescribing of selected medications at the time of hospital discharge. We 
examined the hospital use of cardiac medications that have been shown to be of benefit 
in improving the long-term prognosis of patients with ADHF, namely angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-
blockers, and aldosterone inhibitors. In addition, we examined the use of medications 
shown to be effective in improving patient’s symptomatic status (digoxin, diuretics) and 
selected cardiac medications (lipid-lowering agents, nitrates) [15].  Long-term survival 
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status was obtained by the review of medical records at all participating medical centers 
for further hospitalizations or medical care contacts and review of social security death 
index and statewide death certificates. Follow-up was completed through the end of 
2009 for all patient cohorts. 
 
Data Analysis 
We examined differences in the characteristics of patients with EF values <40%, 
41-49%, and >50% using ANOVA and chi-square tests for continuous and discrete 
variables, respectively.  A life-table approach was used to examine long-term mortality 
following discharge from all central Massachusetts hospitals, including patients with 
varying lengths of long-term follow-up.  Post-discharge case-fatality rates, multivariable 
adjusted relative risks (RRs), and accompanying 95% confidence intervals (CIs) were 
calculated in a standard manner. Multivariable adjusted logistic regression analyses 
were used to examine the association between EF findings and 1 and 2-year post-
discharge mortality while controlling for several clinical and demographic factors of 
prognostic importance including age, sex, history of previously diagnosed atrial 
fibrillation, diabetes, chronic lung disease, renal failure, and HF, and serum glucose 
findings during the acute hospitalization.  The factors chosen for inclusion in the 
regression models were based on established predictors of mortality in the published 
literature and differences between groups at baseline as defined by a p value <0.15.  
We did not control for the receipt of various cardiac medications during the patient’s 
index hospitalization in these regression analyses due to the potential for confounding 
by treatment indication and lack of more detailed information about the timing of therapy 
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administration relative to the onset of ADHF.  The post-discharge mortality time points 
chosen for analysis were selected because of the high death rates observed in patients 
with ADHF during the first several years after hospital discharge.  The Committee for 
the Protection of Human Subjects in Research at the University of Massachusetts 
Medical School approved this study.  
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CHAPTER 3 
Long-Term Survival for Patients with Acute Decompensated Heart Failure 
According to Ejection Fraction Findings 
 
Background:  Limited data exists about the long-term prognosis of patients with acute 
decompensated heart failure (ADHF) further stratified according to ejection fraction (EF) 
findings. 
Methods and Results: The primary objective of this population-based observational 
study was to characterize and compare trends in long-term prognosis after an episode 
of ADHF across 3 EF strata.  Hospital medical records were reviewed for 3,604 
residents of the Worcester (MA) metropolitan area who were discharged after ADHF 
from all 11 medical centers in central Massachusetts during 1995, 2000, 2002, and 
2004 and had EF measurements during their index hospitalization.  The average age of 
this population was 75 years, the majority was white, and 44% were men.  
Approximately 49% of the population had preserved EF HF (HF-PEF) (>50%), 37% had 
reduced EF HF (HF-REF) (<40%), and 14% had borderline EF HF (41-49%) (HF-
BREF). Patients with HF-PEF experienced higher post discharge survival rates than 
patients with either HF-REF or HF-BREF at 1, 2, and 5-years after discharge from all 
central Massachusetts medical centers.  While prognosis at 1-year after hospital 
discharge improved for all patient groups during the years under study, especially for 
those with HF-REF and HF-PEF, these encouraging trends declined with increasing 
duration of follow-up. 
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Conclusion:  In conclusion, although improvements in 1-year post-discharge survival 
were observed for patients in each of the 3 EF groups examined to varying degrees, the 
post-discharge prognosis of all patients with ADHF remains guarded. 
 
INTRODUCTION 
 Acute decompensated heart failure (ADHF) is an increasingly prevalent clinical 
syndrome which is associated with reduced quality of life, a high rate of hospital 
readmissions, and a poor long-term prognosis [73].  One year all-cause death rates 
among patients with ADHF have been reported to be as high as 35% [3,4,75,76].  
Hospital readmission rates are also very high in these patients, with approximately one 
half  of patients with ADHF being readmitted to the hospital within the first 6 months 
after discharge [6].  
In order to optimize the medical management of patients with ADHF, and more 
fully understand and describe the epidemiology of this clinical syndrome, the most 
recent American Heart Association/American College of Cardiology (AHA/ACC) 
guidelines identified 3 groupings based on ejection fraction (EF) findings to further 
stratify patients with HF into varying at risk groups.  These groups are defined as those 
with reduced (EF<40%, HF-REF), borderline (EF=41-49%, HF-BREF), and preserved 
HF (EF>50%, HF-PEF) [4].  Although  the long-term prognosis of patients discharged 
from the hospital after ADHF has been characterized in several longitudinal studies 
[3,5,17,18,19,20,21], including our community-wide study of residents of central 
Massachusetts [5,13], decade long trends in the long-term mortality of patients 
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discharged from the hospital after ADHF, further stratified according to  contemporary 
EF criteria, have not been described.   
 The primary objective of this study was to describe and compare the long-term 
post-discharge prognosis of patients hospitalized with ADHF across several EF strata 
and over time.  Data from the population-based Worcester Heart Failure Study were 
used for this investigation [4,5,13-15].  
 
RESULTS 
Study population characteristics 
Our study population consisted of 3,604 residents of the Worcester metropolitan 
area who were hospitalized at all central Massachusetts medical centers with ADHF 
during the 4 years under study and had EF data available. Their average age was 
approximately 75 years, the vast majority was Caucasian, 44% were male, and the 
majority had a prior history of HF (59%). In this population, 36.9% (n=1,479) were 
classified as having HF-REF (average EF=26.7%), 49.4% (n=1,779) were classified as 
having HF-PEF (average EF=59.9%), and the remaining 13.7% (n=346) were classified 
as having HF-BREF (average EF=43.6%). 
Patients with HF-REF were slightly younger, predominantly male, had the 
greatest co-morbid disease burden, and presented with lower systolic blood pressures, 
but higher BUN and serum hematocrit levels, than did patients with either HF-BREF or 
HF-PEF (Table 3.1).  They were also less likely to have a history of chronic lung 
disease, but were more likely to have a history of previously diagnosed coronary heart 
disease, chronic kidney disease, and HF.   
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Patients with HF-PEF were generally older, mostly female, and presented with 
higher estimated glomerular filtration rate findings at the time of hospital admission than 
patients in the other EF strata.  Patients with HF-PEF were also more likely to have 
presented with a first episode of ADHF and to have a history of chronic lung disease 
and hypertension (Table 3.1).   
 Patients with HF-BREF were slightly older than patients with HF-REF and 
included a higher percentage of women. In addition, they included a greater percentage 
of patients with previously diagnosed peripheral vascular disease compared to patients 
with either HF-REF or HF-PEF (Table 3.1).   
 
Hospital Medication Prescribing Practices 
Overall, as well as over time, patients with ADHF and reduced EF findings were 
more likely than those with preserved EF findings to have received ACE 
inhibitors/ARBs, lipid lowering agents, nitrates, diuretics, and digoxin at the time of 
hospital discharge (Figure 3.1).  Diuretics were prescribed the most to patients with HF-
REF and to a similar extent in the other two categories in 2004 (Figure 3.1B).  Patients 
with HF-PEF were more likely to have been prescribed calcium channel blockers but 
were less likely to have received combinations of ACE/ARBs, beta-blockers, and 
aldosterone inhibitors in comparison to those with either HF-REF or HF-BREF (Figures 
3.1A and D).   
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Post-Hospital Discharge Prognosis  
Overall, the case-fatality rates at 1, 2, and 5 years after hospital discharge were 
approximately 35%, 49%, and 71% for patients with HF-REF; 27%, 42%, and 70% for 
those with HF-BREF;  and 30%, 43%, and 69% for patients with HF-PEF, respectively 
(Table 3.2 and Figure 3.2).  The overall median survival times were approximately 1.9 
years for patients with HF-REF, 2.1 years for those with HF-BREF, and 2.3 years for 
patients with HF-PEF (Figure 3.2).   
At 1, 2, and 5 years after hospital discharge, patients with HF-BREF had the 
highest crude relative risk (RR) of dying compared with patients in the other two groups 
(Table 3).  After adjustment for a variety of important demographic and clinical 
variables, the poorer long-term prognosis for patients with HF-BREF, and for those with 
HF-REF, remained though these differences were no longer statistically significant at 5 
years after hospital discharge (Table 3.3). 
 
Trends in post-discharge survival  
 The 1-year post-hospital discharge survival rates improved for all patients 
discharged from greater Worcester medical centers during the years under study, 
though these trends were only statistically significant for patients with HF-REF in 2004 
as compared to those discharged in 1995 (Table 3.4).  However, lesser degrees of 
improvement in survival were observed at 2 years after hospital discharge for patients 
discharged  in 2004 compared with those discharged in 1995 (Table 3.4).  
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DISCUSSION  
The results of this community-wide study suggest that patients with HF-PEF 
experienced a better prognosis after hospital discharge compared to patients 
discharged after HF-REF or HF-BREF.  While encouraging increases in 1 year survival 
were observed in all patient groups during the years under study, especially for those 
with HF-REF and HF-PEF, these trends were attenuated during subsequent years of 
follow-up and death rates after hospital discharge remained high in all groups.  We 
observed differences in the characteristics of patients with ADHF with preserved, mildly 
impaired, or reduced EF values and the prescription of evidence-based cardiac 
medications at discharge increased over time for all patient groups.   
 
Study population characteristics 
 The baseline characteristics of our 3 ADHF groups were consistent with the 
results of previous observational studies and clinical trials [20,21,53].  We found that 
patients with lower EF findings had a higher burden of several pre-existing 
cardiovascular diseases and were primarily male.  In contrast, patients presenting with 
preserved EF findings were typically older, mostly female, and had a higher prevalence 
of previously diagnosed hypertension and COPD [53].    
A limited number of prior investigations have examined the characteristics of 
patients with borderline EF values [20,21,53].  We found that patients with HF-BREF 
were most similar to those with HF-REF.  This could reflect the inexact science and 
measurement of EF assessment or that patients with HF-BREF represent a distinct 
ADHF subtype.  
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Long-term prognosis of patients with ADHF according to EF findings 
 To date, no studies of patients with ADHF have examined trends in long-term 
prognosis using current ACC/AHA cut points for EF values [3].  The studies that have 
examined the long-term prognosis of patients with ADHF further stratified according to 
EF findings have  used different cut points, some defining HF-PEF as >50% whereas 
others have used  a cut point of >40%, making comparisons between studies difficult 
[53].   
Despite these limitations, data from observational studies have suggested that 
HF patients with preserved EF have a better long-term prognosis than patients with 
reduced EF findings [53,77].  The DIG [78] and CHARM [79,80] clinical trials found that 
patients with  HF-PEF experienced lower all-cause death  rates compared to patients 
with reduced EF findings.  However, the DIG-PEF trial used an EF cutpoint >45% [78] to 
define patients with HF-PEF whereas the CHARM-Preserved trial used an EF cutpoint 
>40% [79] to characterize patients with preserved EF findings.   
The finding that patients with preserved EF have a better long-term prognosis 
than our other comparison groups is consistent with a meta-analysis that pooled data 
from 31 cohort studies and clinical trials [52].  However, a study examining differences 
in the long-term survival of approximately 6,000 patients from Olmsted County, 
Minnesota with HF-REF or HF-PEF found that patients with HF-PEF had only a 
marginally better prognosis at 1 and 5 years after hospital discharge [74].   A Canadian 
study examining 30-day and 1-year mortality rates of 2,802 patients with incident ADHF 
found no differences in these rates between patients with HF-REF and HF-PEF [17].  
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Additionally, similar death rates at 3 months after hospital discharge were observed 
among 20,118 HF patients with reduced EF and 21,149 patients with preserved EF in 
the OPTIMIZE-HF registry [18].   
One possible explanation for these disparate results is that there have been 
considerable improvements in the treatment of patients with HF-REF over time. This 
hypothesis is consistent with a recent study from Olmsted County, Minnesota that 
examined longitudinal changes in EF values in 1,233 patients with newly diagnosed HF 
between 1984 and 2009 [81].  Average EF values decreased by nearly 6% over a 5 
year period for patients with  HF-PEF whereas patients with HF-REF had EF 
measurements that increased by nearly 7% over time, with greater increases in EF 
findings observed in patients treated with evidence-based therapies.   
The results from our population-based study in residents of central 
Massachusetts suggest that patients with HF-REF and HF-PEF experience different 
survival rates during the first several years after hospital discharge, with patients with 
HF-PEF faring slightly better than those with HF-REF; only patients with HF-REF and 
HF-PEF exhibited improvements in 1-year survival after hospital discharge for ADHF 
during the years under study.  None of the patient subgroups examined demonstrated 
significant increases in post-discharge survival thereafter.  One reason for the increases 
in 1-year survival observed for patients with HF-REF may be due in part to the 
enhanced management of these patients based upon evidence-based guidelines.  
 
Medication Prescribing Practices 
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Little data exists describing differences in the prescribing of cardiac medications 
to patients with ADHF with preserved, mildly reduced, or reduced EF values.  Current 
treatment guidelines are designed to treat patients with HF-REF [3] at the time of 
hospital discharge, but few, if any, recommendations exist to treat patients with either 
preserved, or mildly reduced, EF findings.  In our patient cohort, approximately 30% of 
patients with HF-REF were not prescribed ACEI/ARBs and almost 25% were not 
prescribed a beta-blocker at the time of hospital discharge, even during the most recent 
year under study (2004).  Further studies remain needed to better understand patient 
and provider level barriers to potential gaps in the use of evidence-based treatments 
and whether these findings are evident in more recent cohorts of patients hospitalized 
with ADHF.   
Current recommendations for the treatment of patients with HF-PEF are to 
control their blood pressure and volume status [3].  In addition, data from randomized 
clinical trials have demonstrated a lack of efficacy for the use of ARBs in HF patients 
with preserved EF [79,82] and the results from a single randomized trial failed to show 
any efficacy for ACE-inhibitors [83].  We observed an increase during the years under 
study in the prescribing of calcium channel blockers to patients with HF-PEF. Several 
clinical trials have demonstrated an improvement in exercise tolerance and HF related 
symptoms for patients with HF-PEF treated with verapamil [45]. However, no data 
currently exists that suggest that calcium channel blockers improve mortality in patients 
with HF-PEF [40,46].   
We were unable to find any published studies that examined the medications that 
were prescribed to ADHF patients with borderline EF findings at discharge from the 
36 
 
hospital.  Our study suggests that patients with HF-BREF are being treated similarly to 
those with preserved EF in the community setting.  There remains an ongoing need for 
the development of better evidence-based guidelines to treat patients with HF-PEF and 
HF-BREF beyond current measures of blood pressure and volume control to address 
the poor long-term prognosis these and all patients with ADHF face. 
 
Study Strengths and Limitations 
Our study has several strengths including its population-based design and ability 
to examine trends in long-term prognosis over a decade long period in patients from 3 
EF strata.  Since this New England community is predominately white, however, the 
generalizability of our findings to patients of other race/ethnicities may be limited.  We 
did not collect information on patient’s socioeconomic or cognitive status or other factors 
that have been shown to affect long-term prognosis after ADHF.  Additionally, data were 
not collected on patient’s adherence to any prescribed treatments or lifestyle practice 
changes after being discharged from the hospital.  We only had a single measurement 
of EF for each patient and only 2 out of every 5 patients had their EF assessed acutely. 
We could not account for the impact of potentially changing EF values on observed 
long-term mortality patterns and more contemporary data are needed to extend the 
present findings.   
 
CONCLUSIONS 
Despite encouraging trends in survival after the first year after hospital discharge 
for residents of central Massachusetts discharged from all area medical centers after 
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ADHF, the long-term death rates in these patients remain extremely high.  Patients with 
varying EF findings had different demographic and clinical characteristics that need to 
be taken into account when treating these patients.  Finally, the prescribing of effective 
cardiac medications increased over time for all patient groups.  This may have, in part, 
contributed to the observed improvements in post-discharge survival observed across 
all EF strata.  Additional clinical and epidemiologic research utilizing contemporary EF 
criteria remains needed to improve the long-term prognosis of patients who develop 
ADHF. 
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Table 3.1 
Demographic and clinical characteristics of patients 
with acute decompensated heart failure according to ejection fraction (EF) findings 
 Ejection Fraction (%)  
 ≤40 41-49 ≥50  
Variable (n=1,479) (n=346) (n=1,779) p-value 
Age (mean yrs, SD) 73.7 ± 12.8 76.1 ± 11.4 76.5 ± 11.9 <0.01 
Men 836 ± 56.5% 157 ± 45.4% 594 ± 33.4% <0.01 
White 1373 ± 92.8% 319 ± 92.2% 1660 ± 93.3% 0.72 
Length of stay (days) (mean, SD) 7.0 ± 7.3 7.2 ± 7.5 7.6 ± 8.9 0.10 
Hypertension 973 ± 65.8% 250 ± 72.3% 1257 ± 70.7% <0.01 
Atrial fibrillation 515 ± 34.8% 118 ± 34.1% 635 ± 35.7% 0.80 
Diabetes mellitus 593 ± 40.1% 129 ± 37.3% 610 ± 34.3% <0.01 
Coronary heart disease 827 ± 56.0% 189 ± 54.6% 776 ± 43.6% <0.01 
Chronic obstructive pulmonary disease 412 ± 27.9% 112 ± 32.4% 604 ± 34.0% <0.01 
Peripheral vascular disease 299 ± 20.2% 75 ± 21.7% 320 ± 18.0% 0.13 
Stroke 186 ± 12.6% 51 ± 14.7% 212 ± 11.9% 0.34 
Chronic kidney disease 407 ± 27.5% 86 ± 24.9% 386 ± 21.7% <0.01 
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Heart failure 939 ± 63.5% 200 ± 57.8% 978 ± 55.0% <0.01 
Body mass index (kg/m2) 27.5 ± 6.9% 27.9 ± 6.8% 28.7 ± 7.9% <0.01 
Glomerular filtration rate (mL/min/1.73 m2) 51.1 ± 23.2% 50.8 ± 23.2% 53.7 ± 24.0% <0.01 
Systolic BP (mm Hg) 139.8 ± 30.9% 150.6 ± 33.0% 148.1 ± 32.5% <0.01 
Diastolic BP (mm Hg) 77.6 ± 19.5% 78.0 ± 18.6% 74.3 ± 19.7% <0.01 
Glucose (mg/dL) 160.0 ± 70.8% 162.4 ± 76.7% 155.0 ± 66.3% 0.06 
Total cholesterol (mg/dL) 155.4 ± 42.6% 154.9 ± 38.8% 162.1 ± 44.2% 0.11 
Blood urea nitrogen (mg/dL) 33.8 ± 22.6% 31.1 ± 20.5% 30.0 ± 19.7% <0.01 
Serum sodium (mEq/L) 137.2 ± 5.4% 138.0 ± 4.3% 137.5 ± 6.2% 0.48 
Hematocrit (%) 37.2 ± 6.5% 36.1 ± 6.6% 35.9 ± 12.2% <0.01 
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Table 3.2 
Changes over time in post-discharge case-fatality rates according to ejection fraction (EF) findings 
 Ejection Fraction 
 1-year 2-years 5-years 
Period ≤40% 41-49% >50% ≤40% 41-49% >50% ≤40% 41-49% >50% 
Overall 34.8% 26.7% 29.9% 48.9% 41.6% 43.3% 71.1% 69.5% 68.7% 
          
1995 40.4% 25.4% 35.0% 55.7% 38.8% 46.5% 76.2% 68.7% 70.7% 
2000 35.7% 31.3% 30.4% 52.2% 50.6% 46.7% 74.7% 77.1% 71.5% 
2002 32.6% 21.7% 28.9% 44.4% 35.1% 41.2% 67.7% 65.0% 66.9% 
2004 32.6% 28.7% 29.1% 45.9% 42.5% 41.9% 67.9% 67.8% 67.6% 
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Table 3.3 
Relative risk (RRs) for dying after hospital discharge according to ejection fraction (EF) findings 
 1-year 2-years 5-years 
  
Crude RR 
Mutivariable 
adjusted RR* 
 
Crude RR 
Mutivariable 
adjusted RR 
 
Crude RR 
Mutivariable 
adjusted RR 
HF-REF 
(EF≤40%) 
1.12 
(1.02, 1.22)0 
1.17 
(1.07, 1.28) 
1.10 
(1.03, 1.18) 
1.17 
(1.09, 1.24) 
1.03 
(0.99,1.08) 
1.02 
(0.99, 1.05) 
HF-BREF 
(EF=41-49%) 
1.25 
(1.04, 1.49) 
1.37 
(1.14, 1.65) 
1.22 
(1.06, 1.40) 
1.36 
(1.20, 1.55) 
1.06 
(0.97,1.16) 
1.04 
(0.98, 1.10) 
HF-PEF** 
(EF>50%) 
1.0 1.0 1.0 1.0 1.0 1.0 
* Controlling for age, sex, history of atrial fibrillation, diabetes, chronic heart disease, chronic obstructive pulmonary disease, chronic kidney 
disease, and heart failure, and serum glucose levels during hospitalization. 
** Referent group 
0 95% confidence intervals 
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Table 3.4  
Changes over time in crude and multivariable adjusted relative risk (RRs) for dying 
at 1 and  2 years after hospital discharge according to ejection fraction (EF) findings 
 EF≤40% EF=41-49% EF≥50% 
1-Year Crude RR Adjusted RR* Crude RR Adjusted RR Crude RR Adjusted RR 
2000 0.74 
(0.51-1.07)0 
0.69 
(0.50-0.97) 
1.30 
(0.51-3.30) 
0.91 
(0.37-2.28) 
0.73 
(0.47-1.14) 
0.69 
(0.45-1.07) 
2002 0.63 
(0.36-1.10) 
0.58 
(0.35-0.96) 
1.48 
(0.37-5.99) 
0.87 
(0.22-3.46) 
0.62 
(0.32-1.22) 
0.58 
(0.30-1.11) 
2004 0.55 
(0.26-1.14) 
0.48 
(0.25-0.94) 
1.69 
(0.26-10.87) 
0.84 
(0.13-5.23) 
0.53 
(0.22-1.31) 
0.48 
(0.20-1.15) 
       
2-Years       
2000 0.85 
(0.64-1.11) 
0.92 
(0.77-1.09) 
1.53 
(0.78-3.02) 
1.24 
(0.67-2.32) 
0.95 
(0.67-1.35) 
0.89 
(0.64-1.24) 
2002 0.78 
(0.52-1.17) 
0.88 
(0.68-1.14) 
1.90 
(0.69-5.24) 
1.38 
(0.54-3.52) 
0.93 
(0.55-1.57) 
0.84 
(0.51-1.38) 
2004 0.72 0.84 2.35 1.54 0.90 0.79 
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(0.42-1.24) (0.60-1.19) (0.61-9.11) (0.44-5.36) (0.45-1.83) (0.40-1.54) 
 
* Controlling for age, sex, history of atrial fibrillation, diabetes, chronic heart disease, chronic obstructive pulmonary 
disease, chronic kidney disease, and heart failure, and serum glucose levels during hospitalization. 
0 95% confidence interval 
1995 is the referent year for all regression analyses 
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Figure 3.1: Trends in Treatment Practices According to Ejection Fraction Findings 
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Figure 3.2: Trends in Post-Discharge Survival Rates According to Ejection Fraction Findings
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CHAPTER 4 
Magnitude of and prognostic factors associated with post-discharge mortality 
after hospitalization for acute decompensated heart failure according to ejection 
fraction findings. 
 
Background:  Limited data exist, particularly from the more generalizable perspective 
of a population-based investigation, about the magnitude of, and factors associated 
with, long-term prognosis  in patients discharged from the hospital after acute 
decompensated heart failure (ADHF) further stratified according to currently 
recommended ejection fraction (EF) findings.   
Methods:  The hospital medical records of residents of the Worcester (MA) 
metropolitan area who were discharged after ADHF from all 11 medical centers in 
central Massachusetts during the 5 study years of 1995, 2000, 2002, 2004, and 2006 
were reviewed.  Follow-up was completed through 2011 for all patient cohorts. 
Results:  The average age of the 4,293 study patients was 75 years, the majority (93%) 
were Caucasian, and 44% were men.  Of these, 35% (n=1,680) had reduced (REF; 
EF≤40%), 13% (n=377) had borderline (BREF; EF=41-49%), and 52% (n=2,236) had 
preserved EF findings (PEF; EF>50%).  One  and two year post discharge death rates 
were 34% and 53%, 27% and 46%, and 27% and 48% for patients with REF, BREF, 
and PEF, respectively.  Advanced age and lower estimated glomerular filtration rate 
findings at the time of hospital admission were important predictors of 1-year death 
rates, irrespective of EF findings.   Previously diagnosed chronic obstructive pulmonary 
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disease, chronic kidney disease, and atrial fibrillation were associated with a poor 
prognosis in patients with PEF and REF whereas a history of diabetes was an important 
prognostic factor for patients with REF and BREF.   
Conclusion:  We observed differences in several prognostic factors between patients 
with ADHF with varying EF findings, which have implications for more refined treatment 
plans for these patients. 
 
INTRODUCTION 
 Acute decompensated heart failure (ADHF) is a world-wide epidemic that affects 
nearly 6 million adult Americans and results in a substantial number of deaths annually 
[3,4,73,75,76].  Given the aging of the American population, it is predicted that the 
number of adult U.S. men and women who will be diagnosed with ADHF will increase to 
approximately 8 million by 2030 [84].  
In order to better understand and characterize the epidemiology of this 
increasingly prevalent clinical syndrome,  a classification scheme for heart failure has 
been recently created based on ejection fraction (EF) findings [4].  The 2013 American 
Heart Association/American College of Cardiology (AHA/ACC) guidelines defined three 
EF strata [4].  This new classification schema was recommended since several 
research groups had utilized different EF cut-offs for differentiating patients with 
preserved (PEF) from those with reduced ejection fraction (REF) findings,  producing 
varying study results and difficulties in interpretation.  Furthermore, little data exist on 
the prognosis, or factors associated with poor long-term prognosis, of patients with 
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borderline reduced EF values (BREF), especially from the more generalizable 
perspective of a population-based investigation. 
Several epidemiological studies have identified a number of important prognostic 
factors that are associated with poor long-term outcomes for patients with ADHF 
including advanced age, male sex, hyponatremia, lower systolic blood pressure, poorer 
kidney function, and several comorbid conditions [17,20,54,55,56,57,58,59,60,85].  
However, many of these earlier studies examined the role of various prognostic factors 
in patients with heart failure that had not been stratified according to EF findings and, 
among those that did [17,62,63,64,65,66], none used the 2013 AHA/ACC guidelines 
recommending specific EF cutpoints [4].   
 The objectives of the present community-wide study were to describe long-term 
death rates and factors associated with all-cause mortality among patients with ADHF 
further categorized into currently recommended EF strata.  Data from the population-
based Worcester Heart Failure Study were used for this investigation [5,19,70,86]. 
 
RESULTS 
Study population characteristics 
During the 5 periods under study, a total of 4,293 residents of central 
Massachusetts were discharged from all 11 metropolitan Worcester medical centers 
after ADHF and had echocardiography results available for their index hospitalization.  
The average age of this population was approximately 75 years, the majority were 
Caucasian, and about 56% were women (Table 4.1).  In this population, 39% (n=1,680) 
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of patients were considered to have REF (EF≤40%), 9% (n=377) had BREF (EF=41-
49%), and 52% (n=2,236) were classified as having PEF (EF>50%). 
 
Post Discharge Mortality  
Thirty four percent (n=571) of the patients with REF, 27% (n=101) of the patients 
with BREF, and 27% (n=613) of the patients with PEF died during the first year after 
hospital discharge for ADHF.  These death rates increased to 53%, 46%, and 48%, at 2 
years after hospital discharge for our respective comparison groups.  The median 
survival time was 2.2, 2.3, and 2.7 years after hospital discharge for patients with REF, 
BREF, and PEF, respectively.  
 
Characteristics of Deceased Patients 
In comparing the characteristics of patients with REF who died during the first 
year after hospital discharge to patients with REF that survived this high risk period, 
patients that died were older, had longer stays in the hospital during their index 
hospitalization, lower BMIs, and lower blood pressures and estimated glomerular 
filtration rate (eGFR) findings at the time of hospital admission (Table 4.1).  In addition, 
deceased patients with REF were more likely to have previously diagnosed chronic 
kidney disease (CKD), coronary heart disease, chronic obstructive pulmonary disease 
(COPD), atrial fibrillation, and HF.  Patients with BREF who died during the first year 
after discharge were older and had longer hospital stays than those that lived (Table 
4.1).  In addition, they had higher frequencies of previously diagnosed COPD, atrial 
fibrillation, and heart failure (HF), but lower rates of hypertension and peripheral 
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vascular disease (PVD).  Patients with PEF who died during the first year after 
discharge were older, had longer hospital stays, lower eGFR and hematocrit findings, 
but lower serum sodium levels at the time of hospital admission in comparison to those 
that lived (Table 4.1).  In addition, they had higher rates of previously diagnosed CKD 
and atrial fibrillation, but lower rates of previously diagnosed hypertension. Across all EF 
strata, patients who died during the first year after hospital discharge were significantly 
older than those who survived this high risk period (Table 4.1). 
 
Predictors of 1-year Mortality for Patients with ADHF according to EF strata 
 After adjusting for several important clinical and demographic factors, several 
factors were associated with a poorer prognosis during the first year after hospital 
discharge for all study patients (Table 4.2).  Advanced age, a prior history of CKD, and 
atrial fibrillation were important predictors of 1-year mortality for patients with ADHF, 
irrespective of EF findings.  A prior history of COPD was an important predictor of 
mortality for patients with either PEF or REF whereas a history of diabetes was 
associated with higher 1 year death rates in patients with REF.  A lower 
(<30L/min/1.73m2) eGFR was associated with higher one year death rates after hospital 
discharge for patients with ADHF, irrespective of  EF results (Table 4.2). 
 
Impact of Age on Post Discharge Prognostic Factors  
Cox proportional hazard regression models demonstrated advanced age to be a 
highly significant prognostic factor for patients in all EF strata (Table 4.2).  In our study 
population, 45% of patients with REF, 36% of patients with BREF, and 34% of patients 
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with PEF were <75 years old (Table 4.1).  Therefore, we further divided  patients in the 
three EF strata into two age groups, <75 and ≥75 years, for purposes of examining 
whether there  were differences in various prognostic factors between younger and 
older patients hospitalized with ADHF(Table 4.3).   
The important prognostic factors that were associated with increased mortality 
during the first year after hospital discharge for ADHF for comparatively younger 
patients with REF included previously diagnosed diabetes, COPD, CKD, low eGFR 
values.  In contrast, predictors of poor outcomes within the first year after hospital 
discharge for those older than 75 years included PVD and an admission eGFR between 
30-59 (Table 4.3).  COPD was an important prognostic factor for patients with REF and 
PEF, irrespective of age.  Prognostic factors that were associated with dying during the 
first year after hospital discharge for younger patients with BREF were a history of 
diabetes, PVD, and a high admission systolic blood pressure.  A low admission eGFR 
and previously diagnosed COPD were associated with an increased risk of dying for 
patients with PEF, irrespective of age.  Older patients with PEF who had atrial fibrillation 
previously diagnosed were at increased risk for dying during this high risk first year 
period. 
 
DISCUSSION  
The results of this study in residents of central Massachusetts hospitalized at all 
11 area medical centers suggest that patients with ADHF have high 1 and 2-year post 
discharge all-cause mortality rates, with patients with REF having the highest death 
rates at these time points.  In addition, patients with PEF had the longest median 
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survival times as compared with patients in the other two EF strata. Several prognostic 
factors differed between the three EF groups including a prior history of COPD, CKD, 
atrial fibrillation, and diabetes. Advanced age was importantly associated with a poorer 
post-discharge prognosis among all patients discharged from central Massachusetts 
medical centers after hospitalization for ADHF, irrespective of EF findings.  A low eGFR 
was associated with an increased risk for 1-year mortality after hospitalization for ADHF 
across the three EF strata.  When the study population was further stratified according 
to age, different prognostic factors became important predictors of post discharge 
mortality.   
 
Study population characteristics 
 Previously published observational studies and clinical trials have primarily 
examined differences in the demographic and clinical characteristics of patients with 
either PEF or REF, with few describing the characteristics of patients with BREF 
[12,20,21,53].  These studies found that HF patients with lower EF values had a higher 
burden of pre-existing diseases, including coronary heart disease and renal failure, and 
were primarily male.  In contrast, patients presenting with preserved EF findings were 
typically older and mostly female.  Our findings suggest that patients with BREF appear 
to represent an intermediate group with characteristics of patients with PEF and REF.  
These findings suggest that ADHF is a heterogeneous condition with distinct group 
characteristics whose prognosis may differ and whose long term management might 
need to be approached differently. 
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Post-hospital discharge mortality  
There have been mixed published findings  as to which EF strata has a better 
long-term survival after developing ADHF, with some groups  suggesting that patients 
with PEF fare better and other groups suggesting that patients with PEF and REF have 
similar mortality rates after hospital discharge [17,62,63,64,65,66].  In the present study 
we observed that patients with PEF fared better over our period of long-term follow-up 
than patients with either REF or BREF.  Our findings of higher death rates in patients 
with REF are consistent with the observation that patients with PEF typically have more 
non-cardiovascular comorbidities than patients with REF [87].  However, there are no 
clinical guidelines for the treatment of patients with PEF, suggesting that their lower 
discharge mortality might be less a factor of how these patients are managed and more 
a function of the underlying pathophysiology associated with PEF.  This is supported by 
the observation that ACE/ARBs and beta-blockers are effective in patients with REF but 
not in those with PEF [16].  
 
Characteristics of patients that died at 1-year post-hospital discharge 
 Patients in each of the three EF strata that died within the first year after hospital 
discharge compared to patients who survived this period exhibited significant 
differences in several baseline characteristics which were not the same between 
patients in the three EF strata examined.      
 Studies that have stratified patients with HF into groups based on EF findings 
and examined predictors of mortality have typically only assessed two strata, those with 
preserved and those with reduced EF findings [17,62,63,64,65,66].  A number of factors 
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that were associated with long-term mortality were common between the PEF and REF 
groups; however, several predictors were also unique to one group or the other.  
Obesity is a common finding in patients with PEF and a U-shaped relationship with 
adverse outcomes has been observed in which the greatest proportion of adverse 
outcomes occurs among patients in the lowest and highest BMI categories. In our study, 
lower rates of overweight patients were observed in patients with REF that died during 
the first year after hospitalization for ADHF. 
Our findings suggest that patients with REF who died after hospital discharge 
were more likely to have a prior history of COPD, CKD, and diabetes whereas patients 
with PEF who died were more likely to have a history of COPD, CKD, and atrial 
fibrillation than those who survived. Previous reports have identified renal failure and 
PVD as important predictors of poorer long-term survival in patients with REF or PEF 
(15,17); diabetes and COPD have been associated with  higher post hospital discharge 
death rates in patients with PEF (15,17,20).  None of the previous reports described, 
however, included patients with BREF.  Our investigation found that diabetes and CKD 
(eGFR <60 mL/min/1.73m2) were significantly associated with an increased risk of dying 
for patients with REF.  Often present as comorbidities, diabetes and chronic kidney 
disease are common causes of heart failure, and the risk of death in HF may be more 
strongly associated with a decline in the GFR than with a reduction in EF [88]. The 
discrepancies between the current findings and the previous literature could be due to a 
number of factors including comparatively small numbers of women, use of clinical trial 
data, different HF diagnostic criteria [61], exclusion of patients with BREF [17], and the 
EF strata that were used.  Future studies should employ the same EF strata as were 
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proposed in the 2013 AHA/ACC guidelines [4] to ensure that studies can be adequately 
compared.  Further work remains needed to understand the impact of various chronic 
conditions and socio-demographic, psychosocial, and clinical factors on the overall 
mortality of patients with ADHF further divided according to currently recommended EF 
strata.   
 
Impact of age on prognostic factors affecting long-term mortality  
 Age had a significant impact on the factors associated with long-term prognosis 
for patients in each of the EF strata examined in the present study.  Additionally, the two 
age groups we analyzed had different prognostic factors within the same EF group.  
Diabetes and atrial fibrillation, which have been reported to be important prognostic 
factors in patients with ADHF [12,53,67], appeared to have a differential impact based 
on EF strata and age.  In addition, COPD was an important prognostic factor for 
patients with REF and PEF, but not for those with BREF.  One possibility for this 
observation is that the pathophysiological processes that result in BREF might be 
different than either PEF or REF or that these patients are being incorrectly diagnosed 
and treated.  Taken collectively, these findings suggest that age and EF findings should 
be considered when designing appropriate treatment plans for patients with ADHF. 
Future clinical trials should include older patients with different comorbidities to better 
understand the effects of age and selected comorbidities on ADHF, its various EF 
strata, and the management of this clinical syndrome and its various subtypes.    
 
Study Strengths and limitations 
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Our study has several strengths including its population-based design and 
inclusion of only validated cases of ADHF which occurred among adult patients of all 
ages from a well-defined and characterized large metropolitan area.  On the other hand, 
since this New England community is predominantly white, the generalizability of our 
findings to other race/ethnicities may be limited.  In addition, more contemporary data 
are needed to extend the present findings.  We also did not collect information on 
patient’s socioeconomic or cognitive status, serum biomarkers, or other factors that 
have been shown to affect long-term prognosis after ADHF.  Finally, we only had a 
single EF measurement from the index hospitalization for each patient.  Since EF 
findings may change over time [81], we cannot account for the impact of potentially 
changing EF values over time, and  how these changes may affect the mortality profile 
of at risk patients.  
 
CONCLUSIONS  
 Patients with ADHF experience high death rates after discharge from the 
hospital, with approximately one half dying by two years, irrespective of EF strata.  The 
highest post discharge mortality rates were observed for patients with REF.  The results 
of our study suggest that prognostic factors that are associated with mortality within one 
year after hospital discharge differ between patients in the various EF strata with 
advanced age having a large impact on which prognostic factors are important 
determinants of mortality.  This study reinforces ongoing discussions that different 
treatment guidelines may be needed for patients with PEF, REF, and BREF in order to 
design more personalized treatment plans for each of these high risk groups. 
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Table 4.1 
 
Characteristics of patients with acute decompensated heart failure according to ejection fraction (EF) findings and 1 year 
survival status  
       
 REF  
(EF<=40%) 
 BREF  
(EF=41-49%) 
 PEF 
(EF>=50%) 
 
 Alive Dead Alive Dead Alive Dead 
Demographics  (n=1,109) (n=571) (n=276) (n=101) (n=1,623) (n=613) 
Age (mean yrs, +/- 
SD) 
72.0(13.3) 77.0(11.7)** 75.3(11.4) 79.3(10.3) 76.2(12.2) 78.4(12.2)* 
       
<65, n(%) 274(78.1) 77(21.9)** 43(89.6) 5(10.4)* 270(79.7) 69(20.4)* 
65-74 283(73.3) 103(26.7)** 65(73.9) 23(26.1)* 308(74.2) 107(25.8)* 
75-84 385(61.3) 243(38.7)** 111(71.6) 44(28.4)* 611(71.4) 245(28.6)* 
>85 142(53.0) 126(47.0)** 41(60.3) 27(39.7)* 361(68.9) 163(31.1)* 
Male, n (%) 652(58.8) 324(56.7) 125(45.3) 44(43.6) 533(32.8) 213(34.7) 
White, n (%) 999(90.1) 547(95.8)* * 254(92.0) 96(95.1) 1,503(92.6) 588(95.8)* 
Body mass index 
(mean kg/m2) 
28.2(7.0) 26.1(6.2)* 28.5(6.9) 26.1(7.3) 29.3(8.0) 27.4(7.7) 
Length of hospital 
stay, days (mean) 
6.3 8.2* 6.2 9.7** 6.1 10.6** 
       
Co-morbidities, n 
(%) 
Atrial fibrillation 
 
377(34.0) 
 
220(38.5) 
 
82(29.7) 
 
47(46.5)* 
 
566(34.9) 
 
260(42.4)* 
Chronic obstructive 
pulmonary disease  
296(26.7) 181(31.7)* 87(31.5) 41(40.6) 555(34.2) 229(37.3) 
Chronic kidney 
disease 
282(25.4) 204(35.7)** 65(23.6) 31(30.7) 361(22.2) 177(28.8)** 
Coronary heart 
disease 
     598(53.9) 349(61.3)* 147(53.3) 60(59.4) 730(45.0) 272(44.3) 
Diabetes 423(38.1) 240(42.0) 104(37.7) 37(36.6) 573(35.3) 210(34.2) 
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Heart failure  687(62.0) 415(72.7)** 156(56.5) 67(66.3) 921(56.8) 361(58.8) 
Hypertension 757(68.3) 373(65.3) 211(76.5) 65(64.4)* 1,225(75.5) 412(67.1)** 
Peripheral vascular 
disease 
204(18.4) 140(24.5)* 69(25.0) 18(17.8) 323(19.9) 125(20.4) 
Stroke 138(12.4) 75(13.1) 41(14.9) 18(17.8) 195(12.0) 81(13.2) 
       
       
Laboratory 
variables (mean +/- 
SD) 
      
Estimated 
glomerular filtration 
rate (mL/min/1.73 
m2) 
54.9(22.8) 44.0(22.0) 51.2(22.3) 48.4(24.8) 53.9(23.0) 49.6(24.8)* 
Systolic blood 
pressure (mm Hg) 
143.6(30.5) 131.1(28.9) 151.2(33.2) 144.6(30.4) 149.2(31.8) 140.6(32.3) 
Diastolic blood 
pressure (mm Hg) 
80.5(19.5) 71.7(18.1)* 77.3(18.7) 76.5(18.4) 74.4(19.3) 71.0(19.5) 
Serum glucose 
(mg/dL) 
157.0(67.8) 160.2(72.7) 165.8(77.0) 151.2(68.8) 153.0(65.1) 154.0(65.9) 
Serum total 
cholesterol (mg/dL) 
157.3(42.2) 148.0(41.2) 154.6(39.8) 146.1(34.4) 156.3(42.5) 160.0(45.1) 
Serum sodium 
(mEq/L) 
137.8(5.4) 136.6(5.3) 138.2(4.1) 138.1(4.8) 137.9(5.0) 137.0(7.9)** 
Hematocrit (%) 37.8(6.5) 36.2(6.4) 36.3(6.6) 35.7(6.6) 36.3(12.7) 34.6(6.3)** 
       
* p<0.05   
**p<0.001 
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Table 4.2 
 
Factors associated with 1 year mortality according to ejection fraction (EF) strata 
    
 REF(EF<=40%) BREF(EF=41-49%) PEF(EF>=50%) 
 (n=1,384) (n=334) (n=1,646) 
Demographics    
 HR       95% CI HR       95% CI HR       95% CI 
Age (yrs)    
75-84 1.25(1.06,1.46) 1.55(1.07,2.24) 1.30(1.10,1.53) 
>85 2.19(1.90,2.52) 2.82(2.00,3.97) 1.84(1.60,2.11) 
    
Comorbidities    
Chronic obstructive pulmonary 
disease  
1.23(1.09,1.38) 1.21(0.95,1.53) 1.28(1.15;1.42) 
Chronic kidney disease 1.61(1.42,1.82) 1.29(1.00,1.67) 1.31(1.16,1.48) 
Diabetes 1.14(1.02,1.27) 1.20(0.95,1.51) 1.03(0.93,1.14) 
Atrial Fibrillation 1.21(1.07,1.36) 1.31(1.04,1.65) 1.41(1.27,1.57) 
    
Laboratory variables    
Estimated glomerular filtration rate 
<30 
 
2.39 (1.91,2.99) 
 
1.67(1.22,1.80) 
 
1.59 (1.32,1.91) 
30-59 1.42(1.23,1.65) 1.22(0.96,1.55) 1.11 (.98,1.26) 
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Table 4.3 
 
Factors associated with  1-year mortality after hospital discharge further stratified according to ejection fraction and 
age   
 
       
 REF (EF<=40%) BREF (EF=41-49%) PEF (EF>=50%) 
 <75 years   >75 years  <75 years >75 years  <75 years >75 years  
(n=614) (n=681) (n=129) (n=205) (n=566) (n=1,076) 
Comorbidities HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Chronic obstructive pulmonary 
disease  
1.25(1.03,1.
50) 
1.44(1.22,1.7
0) 
1.35(0.87,2.
10) 
1.21(0.83,1.75
) 
1.45(1.20,1.7
5) 
1.29(1.13,1.4
8) 
Chronic kidney disease 1.34(1.06,1.
71) 
1.14(0.94,1.3
8) 
1.64(0.98,2.
75) 
0.75(0.46,1.24
) 
1.12(0.88,1.4
3) 
1.08(0.91,1.2
9) 
Hypertension 0.86(0.72,1.
02) 
0.93(0.79,1.0
8) 
0.71(0.44,1.
14) 
1.01(0.68,1.49
) 
0.94(0.78,1.1
5) 
0.94(0.81,1.0
8) 
Diabetes 1.22(1.00,1.
48) 
1.02(0.86,1.2
1) 
1.47(0.90,2.
41) 
1.44(0.98,2.11
) 
1.21 
(0.99,1.49) 
1.03(0.88,1.1
9) 
Peripheral vascular disease 1.18(0.95,1.
46) 
1.33(1.10,1.5
9) 
1.61(1.00,2.
60) 
0.91(0.61,1.35
) 
1.01(0.80,1.2
8) 
1.06(0.90,1.2
5) 
Stroke 1.41(1.08,1.
83) 
0.94(0.76,1.1
6) 
1.32(0.74,2.
33) 
1.33(0.83,2.11
) 
1.48(1.12,1.9
5) 
1.04(0.86,1.2
5) 
Atrial fibrillation 1.01(0.83,1.
23) 
1.07(0.91,1.2
5) 
1.25(0.78,2.
02) 
1.20(0.88,1.64
) 
1.31(1.07,1.6
2) 
1.39(1.22,1.5
8) 
Coronary heart disease 1.10(0.92,1.
31) 
1.02(0.86,1.2
0) 
1.33(0.84,2.
09) 
1.03(0.73,1.44
) 
1.00(0.83,1.2
1) 
0.88(0.77,0.9
9) 
Laboratory variables      
Estimated GFR (L/min/1.73m2) 
    <30   2.33(1.72,3.
16) 
1.63(1.28,2.0
8) 
1.67(0.93,3.
02) 
1.24(0.67,2.2
7) 
1.45(1.09,1.9
4) 
1.54(1.24,1.92
) 
    30-59 1.24(1.03,1.
50) 
1.27(1.07,1.5
2) 
1.05(0.66,1.
67) 
0.88(0.62,1.2
4) 
0.96(0.78,1.1
7) 
0.98(0.85,1.12
) 
Systolic blood pressure (mmHg) 
61 
 
   150-159 0.52(0.36,0.
75) 
0.71(0.53,0.9
4) 
2.99(1.06,8.
43) 
1.05(0.53,2.1
0) 
0.81(0.54,1.2
3) 
0.81(0.58,1.12
) 
    >160 0.44(0.29,0.
64) 
0.58(0.42,0.7
9) 
2.63(0.93,7.
40) 
0.92(0.46,1.8
4) 
0.70(0.46,1.0
6) 
0.75(0.53,1.05
) 
Serum sodium (mEq/L) 
     >135 0.63(0.51,0.
77) 
0.91(0.76,1.0
8) 
0.66(0.38,1.12
) 
1.01(0.64,1.5
9) 
0.89(0.71,1.1
1) 
0.98(0.84,1.
13) 
 
 
** Referent groups for laboratory variables were GFR >60 mL/min/1.73 m2, systolic blood pressure <100 mmHg, and serum 
sodium <135 mEq/L. 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
Acute heart failure (ADHF) is a significant public health and clinical problem in 
the US and worldwide [3].  This clinical syndrome is the leading cause of 
hospitalizations in the elderly, accounting for approximately one million hospital 
admissions annually [4,6,7], and is an important cause of morbidity, mortality, and 
functional disability.  Recent efforts have attempted to identify better methods for the 
enhanced prevention and prognosis of patients with ADHF.  One noninvasive diagnostic 
test that is used to stratify patients into different prognostic categories is EF findings, 
which quantitatively differentiates patients into various groups, including those with 
reduced, borderline, and preserved EF.  Limited data exists, however, as to the long-
term prognosis of patients with HF further subdivided into these three EF strata, which 
this thesis has attempted to address.          
 The three main objectives of this thesis were to: 1) describe the characteristics of 
the three EF subtypes of patients hospitalized with ADHF; 2) examine the long-term 
prognosis of patients after hospital discharge for ADHF stratified according to three EF 
strata; and 3) determine if there were any prognostic factors associated with an 
increased risk of dying within the first year after hospital discharge for patients with 
reduced, borderline, and preserved EF findings.  Data from the WHFS were used to 
address these three primary objectives. 
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Objective #1: Characteristics of patients with reduced, borderline, and preserved 
EF 
We observed that patients in the three EF strata had different demographic and 
clinical characteristics.  Patients with HF-REF were slightly younger, predominantly 
male, presented with lower systolic blood pressure findings at the time of hospital 
admission, and had higher BUN and serum hematocrit levels at the time of hospital 
admission than did patients with either HF-BREF or HF-PEF (Chapter 3).  They were 
also less likely to have a history of chronic lung disease, but were more likely to have a 
history of previously diagnosed coronary heart disease, chronic kidney disease, and HF.  
Patients with HF-PEF were older, mostly female, and presented with higher eGFR 
findings at the time of hospital admission than patients in the other EF strata.  In 
addition, these patients were more likely to present with a first episode of ADHF and to 
have a history of chronic lung disease and hypertension.       
 We are one of only a few groups to describe the characteristics of patients with 
HF-BREF, who had characteristics relatively similar to the other two groups but were 
slightly older than patients with HF-REF and included a higher percentage of women. In 
addition, they included a greater percentage of patients with previously diagnosed 
diabetes and PVD compared to patients with either HF-REF or HF-PEF.  The different 
demographic and clinical characteristics we observed in this study should be taken into 
account when treating these patients.  Further characterization of patients in these three 
EF strata should be conducted in more contemporary cohorts of patients with ADHF in 
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order to provide a more in depth understanding of these groups and to provide current 
insights into their management and natural history. 
 
Objective #2: Long-term outcomes of patients discharged from the hospital after 
ADHF according to EF strata 
Results from this investigation provide insights into  whether patients with HF-
PEF fare better over the long-term than patients with HF-REF or those with HF-BEF.  
The long-term death rates in patients with ADHF were extremely high, with half of 
discharged patients dying by two years, irrespective of EF strata.  However, patients 
with HF-PEF experienced slightly better prognosis during the first 5-years after 
discharge compared to patients with HF-REF or HF-BREF.  Overall, the case-fatality 
rates at 1, 2, and 5 years after hospital discharge were approximately 35%, 48%, and 
71% for patients with HF-REF; 30%, 46%, and 71% for those with HF-BREF;  and 30%, 
43%, and 69% for patients with HF-PEF, respectively (Chapter 3).  After multivariable 
adjustment, patients with HF-BREF had the highest risk of dying compared with patients 
in the other two groups.  In addition, although the average survival times for all patient 
groups  was approximately 2 years, the longest mean survival times were observed  in 
patients with preserved EF findings (Chapter 3 and 4).  We also observed an increase 
in mean survival times when the 2006 cohort was included in our analyses of between 3 
to 4 months for each of the three groups, with patients with HF-PEF having the longest 
mean survival time of 2.7 years. 
Stratification of patients into clinically meaningful subgroups to more accurately 
identify those patients requiring more aggressive monitoring and treatment from those 
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that might not remain of considerable importance to practicing clinicians.  In addition to 
the lives saved and improvements in quality of life for patients with ADHF, these efforts 
would hopefully translate into health care savings with reduced hospitalizations and 
decreased prescription drug costs.   
 
Objective #3: Prognostic factors associated with an increased risk of dying 
during the first year after hospital discharge for ADHF 
 The prognostic factors that were associated with mortality within one year after 
hospital discharge differed between the three EF strata with advanced age having a 
large impact on which prognostic factors were important determinants of mortality in all 
patient groups.  In addition to the major prognostic impact of advanced age, patients 
with a prior history of diabetes and high BUN levels at admission were also associated 
with an increased risk of dying, irrespective of EF findings.  The prognostic factor 
associated with mortality for patients with either PEF or REF was a prior history of 
chronic lung disease/COPD whereas a history of renal failure was a predictor of 
decreased mortality for patients with REF.  Only atrial fibrillation was associated with 
increased discharge mortality for patients with PEF (Chapter 4).   
When age (the cut-off being 75 years old) was used as a stratifying variable, the 
prognostic factors associated with lower post discharge survival changed significantly.  
Diabetes, a low glomerular filtration rate (GFR), high systolic BP findings , and high 
serum sodium levels at the time of  hospital admission were associated with a poorer 
post discharge survival for patients with REF who were younger than 75 years old..  
Patients with REF who were older than 75 years had a poor 1-year discharge survival if 
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they also had a history of PVD and an admission GFR between 30-59 L/min/1.73m2 
(Chapter 4).  Chronic lung disease/COPD remained an important prognostic factor for 
patients with REF and PEF, irrespective of age.  Diabetes and stroke were associated 
with an increased risk of dying for patients with BREF that were younger than 75 years 
old.  A low admission GFR was associated with death within the first year after 
discharge for patients with PEF, irrespective of age.  Finally, atrial fibrillation was 
associated with increased one-year death rates for older patients with PEF.  A better 
understanding of the prognostic factors associated with a poor discharge survival would 
hopefully lead to more tailored therapies that will improve the long-term outcomes for 
patients with ADHF.  Further work should also investigate the factors associated with 
hospital readmissions, overall and during select high risk periods, since this should 
result in decreased utilization of healthcare services and decreased costs.  Finally, 
using EF as the sole variable to stratify patients with ADHF might not be able to fully 
differentiate high versus low risk patients.  Several additional clinical variables, in 
addition to EF findings, should be identified and incorporated into future predictive 
models. 
 
Future Directions 
The results of this large observational study indicate that patients with ADHF 
have a very poor long-term prognosis. On the other hand, patients with a preserved EF 
fared slightly better than patients in the other two EF strata.  Further clinical and 
epidemiologic research utilizing contemporary EF criteria in more recently hospitalized 
patient cohorts remains needed to improve the long-term prognosis of patients who 
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develop ADHF.  In addition, studies exploring preventive methods and novel 
therapeutics are urgently needed.  Better life style interventions after the patient is 
discharged from the hospital to prevent decompensation and readmission are also 
needed.  These interventions could include methods to increase adherence to effective 
cardiac medications and dietary restrictions including smartphone applications and 
reducing the intake of sodium.  Another avenue with the potential to improve the quality 
and length of life for patients, but is currently speculative, is the use of RNAi-based 
therapeutics, which might be able to prevent the development of ADHF or treat ADHF 
and prevent it from worsening.  RNAi-based therapeutics have  the potential to 
selectively reduce the amount of proteins that cause the pathology associated with 
ADHF,  but with fewer side effects than current medications, which remains  needed at 
present  for patients with ADHF.  
In conclusion, EF measurements differentiate patients with ADHF into three 
groups with different patient characteristics, outcomes, and prognostic factors 
associated with increased mortality.  Further work is needed in the areas of prevention, 
diagnosis, and treatment to improve the lives and associated meaningful health 
outcomes of patients with ADHF. 
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